March 10, 2026

European Healthcare Software: A Structural Opportunity for Growth Investors

Healthcare software has quietly become one of the most compelling investment categories in European venture and growth equity. Driven by structural demand and digitization, the sector is entering a new phase of scalable growth.

With $67 billion deployed globally in 2024 and $660 billion cumulatively over the past decade, healthcare consistently ranks as the second-largest VC investment category after enterprise SaaS, according to Dealroom. Yet the European opportunity remains not only distinct from its American counterpart but, in many ways, more attractive to investors who understand the underlying dynamics.

At Revaia, our experience investing in healthcare workforce management last year culminated in the successful exit of Hublo, which was sold to Five Arrows, which became the company’s majority shareholder. We have since chosen to reinvest alongside Five Arrows through a dedicated vehicle, reflecting our conviction that European healthcare software represents fertile ground for disciplined growth investors. However, the playbook isn't about chasing unicorn valuations or burning capital on premature international expansion. It's about identifying capital-efficient local champions with genuine product-market fit, defensible data advantages, and clear paths to PE-backed consolidation.

The Structural Case for Healthcare Software

The macro tailwinds driving healthcare software adoption are both powerful and durable. Aging populations across Europe are straining healthcare systems already operating under significant budget constraints. Chronic disease prevalence continues rising. Healthcare practitioners are experiencing burnout at unprecedented levels, creating an urgent demand for productivity-enhancing tools. And despite decades of digitization efforts, vast swaths of healthcare operations remain surprisingly analog.

Consider that approximately $265 billion of the $4 trillion spent annually on US healthcare is attributable to administrative waste, according to Revaia analysis. European systems face similar inefficiencies, creating substantial opportunities for software solutions that deliver measurable ROI, whether through workforce optimization, clinical decision support, or operational automation.

The COVID-19 pandemic accelerated digital adoption across healthcare, but the transition remains incomplete. Legacy IT systems persist in most hospital environments. Data silos fragment patient information across care settings. Integration challenges create barriers to entry but also moats for incumbents who successfully navigate them.

Five Categories, Different Dynamics

Healthcare IT spans five broad categories, each with distinct investment characteristics:

Electronic Health Records (EHRs) and Clinical Information Systems form the data backbone of patient care. These platforms centralize health conditions, treatment histories, and clinical documentation. Privacy and security requirements are paramount, and switching costs tend to be high once systems are embedded in clinical workflows.
Revenue Cycle Management addresses billing, coding, and payment collection. This is a massive $138 billion market growing at 12% annually. However, this category skews heavily toward the US, where the complexity of insurance-based reimbursement creates pain points largely absent in European single-payer or hybrid systems.
Operations software encompasses everything from scheduling and practice management to telemedicine and resource allocation. This is where workforce management solutions play a role, addressing the critical need for seamless staffing and care continuity amid rising caregiver shortages.
Analytics is the fastest-growing segment, with a 24% CAGR, driven by AI applications in diagnostics, clinical decision support, and population health management. Importantly, the most effective healthcare AI typically relies on traditional machine learning trained on specific patterns such as radiographic images, genomic sequences, or pathology slides, rather than large language models. The algorithms need to recognize disease signatures, not generate text.
Infrastructure and Compliance covers security, credentialing, and governance. These are increasingly important as healthcare systems face escalating cyber threats while operating on dated IT infrastructure that makes them attractive targets for ransomware attacks.

For European investors, analytics, operations, and EHR categories offer the richest opportunity set. Revenue cycle management remains predominantly a US play, given different reimbursement structures across the Atlantic.

Winning in European Healthcare Software

Our investment experience has crystallized several characteristics that distinguish successful healthcare software companies from also-rans:

Capital efficiency matters more than growth at all costs. Healthcare software sales cycles are long, hospital budgets are constrained, and integration complexity adds friction to every deployment. Companies that maintain disciplined burn while building recurring revenue create optionality that high-burn competitors lack. The most attractive businesses generate meaningful ARR per employee and demonstrate clear paths to profitability.
Data advantages compound over time. Healthcare software companies that accumulate proprietary datasets such as millions of patient records, thousands of practitioners, and years of clinical data build moats that become increasingly difficult to replicate. These data assets enable product improvements, support AI/ML capabilities, and create genuine network effects when platforms connect multiple stakeholders.
Local market leadership trumps premature internationalization. European healthcare operates across 27 distinct regulatory frameworks. Each country has unique reimbursement structures, IT integration requirements, and clinical workflows. Companies that attempt pan-European expansion before achieving dominance in their home market often burn capital without establishing defensible positions anywhere. The better playbook: become the undisputed leader locally, then expand methodically. Or, let a PE acquirer fund the international buildout post-exit.
Integration complexity is both a barrier and a moat. Healthcare IT systems are notoriously fragmented and difficult to integrate. Companies that successfully embed in clinical workflows by becoming systems of record rather than point solutions achieve stickiness that drives exceptional gross retention rates. The flip side is that products requiring heavy IT integration face longer sales cycles and may see margins compressed by third-party integrators.
Sell to the right buyer. Healthcare practitioners often aren't natural software buyers. Independent physicians lack procurement sophistication; hospital clinicians defer to IT and administration. The most successful companies we've observed target HR directors, CFOs, or operations leaders with clear ROI propositions such as reducing costs, generating revenue, or eliminating demonstrable waste.

The M&A Exit Pathway

European healthcare software exits increasingly flow through private equity rather than strategic acquirers or public markets. This dynamic works in favor of growth investors who can position companies as attractive platform acquisition targets.

Corporate acquirers do pay premiums, approximately 36% higher revenue multiples than PE deals based on recent transaction data. But PE firms drive deal volume, and their appetite for European healthcare software continues growing.

The transaction data tells a compelling story. Recent European healthcare software deals have commanded 7-12x revenue multiples, with premium assets achieving ARR multiples of 10x+. EBITDA multiples cluster around 15-25x for quality businesses. PE firms backed by substantial dry powder are comfortable writing checks of €200 million to €1 billion+ for platform companies with consolidation potential.

Strategic buyers remain relevant. These include large healthcare IT conglomerates, device manufacturers diversifying into software, and well-funded category leaders pursuing bolt-on acquisitions. But for most European healthcare software companies, the natural exit runs through PE-backed platforms executing buy-and-build strategies.

Public markets offer limited near-term upside in Europe. Listed healthcare software vendors like CompuGroup Medical and Cegedim trade at compressed multiples reflecting low growth and legacy business challenges. US public markets reward exceptional businesses. Veeva and Doximity command 13-16x revenue. But these represent near-monopolies in their respective niches rather than typical outcomes.

Emerging Themes

Several trends are reshaping the European healthcare software landscape in ways that create investment opportunities:

AI-enhanced diagnostics are among the most compelling AI applications across enterprise software. Machine learning algorithms increasingly match or exceed human accuracy in detecting abnormalities across radiology, pathology, and genomic analysis. The challenge lies in embedding these tools into clinical workflows without disrupting established processes.
Voice and ambient documentation tools are transforming how practitioners capture clinical notes. AI scribes that auto-generate medical records from conversations promise to meaningfully reduce administrative burden. This represents a genuine "magic" value proposition in an industry drowning in documentation requirements.
Remote monitoring and home care solutions address the shift toward preventive care and aging in place. Smartphones, wearables, and IoT devices now generate continuous health data outside clinical settings. Software that aggregates, analyzes, and acts on this data creates value for patients seeking to avoid hospitalization and payers seeking to reduce costs.
Regulatory tailwinds in certain markets are driving adoption. Germany's multi-billion-euro hospital modernization initiative (KHZF) mandates the use of digital discharge and care coordination tools. France's genomic plan promotes the adoption of precision medicine. These government-backed programs create demand catalysts for software vendors positioned to address compliance requirements.

The Optimism Thesis

European healthcare software offers growth investors a compelling combination: massive addressable markets driven by secular tailwinds, fragmented competitive landscapes ripe for consolidation, and clear exit pathways through an active PE buyer universe.

The playbook requires patience with long sales cycles, discipline around capital deployment, and realistic expectations about international expansion timelines. The companies that win tend to be local heroes that are dominant in their home markets, capital-efficient in their operations, and deeply embedded in customer workflows.

For investors who understand these dynamics, the European healthcare software opportunity is substantial. The next generation of category leaders is being built now, and the exit environment has never been more favorable for quality assets.

—
Sources: PitchBook data, Revaia internal analysis, and publicly available company information.